ClinicalTrials.gg
RecruitingNCT07058207CANOBESEUpdated Nov 12, 2026

Weight Management in Obese Cancer Patients During Curative Active Treatment

An interventional study of Multimodal weight management program in Obesity, Solid Neoplasm and Stage II-IV, sponsored by Institut d'Investigació Biomèdica de Bellvitge. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Institut d'Investigació Biomèdica de Bellvitge · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Nov 12, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 390 studies in Obesity with a site in Spain — 95 open to participants now, 134 under way, 45 of them phase 3. Obesity · Spain.

Planned enrollment
256th of 332
50 · median 124
Started
2025
with 51 others
No phase
220 of 390
41 open now
Primary completion
2027-03
later than 62 of 133 live
Registered
310th of 390
by date

Among the 390 studies in Obesity with a site in Spain, this one is the 256th largest by planned enrollment of the 332 interventional ones that give a count, is one of 52 that started in 2025, is one of 220 with no phase, reaches primary completion later than 62 of the 133 other live ones, and was the 310th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

95 of the 390 studies in Obesity with a site in Spain are open now. Recruiting first, the newest first:

90 more — sign in →

All 95 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 390 studies in Obesity with a site in Spain, or all of them as a file.
02

Study summary

This is a feasibility study intervention to fifty cancer patients with obesity and with newly diagnosed stage II-IV solid tumors undergoing curative treatment recruited at the Catalan Institute of Oncology (ICO) in L'Hospitalet, Spain.

The investigators hypothesize that weight management during cancer treatment could enhance health outcomes for this population. The feasibility of a multimodal weight loss management program will be assesses, including a personalized hypocaloric and high-protein diet combined with a supervised exercise home-program and behavioural support.

Read the detailed description

The single-arm intervention will consist of a multimodal weight management program, including a personalized hypocaloric and high-protein diet combined with a supervised exercise home-program and behavioural support. Hypocaloric diet will be individualized according to their energy requirements estimated and then applying a 20% caloric restriction. In order to reduce body weight and maintain muscle mass, a high-protein diet will be provided consisting of 1.5 g of protein/kg/day.

Participants will be provided with a 3-day food record (3-DFR) chart prior to their baseline visit. After a full nutritional evaluation, the dietitian will create a diet plan unique to the participant. For those participants struggling to attain their recommended intake or anticipating protein intake to be challenging, an oral whey powder supplement will be provided for the duration of the study. Additional approaches to overcoming dietary challenges will include information/resources on nutritional symptom management that can impact dietary intake and/or high-protein recipes.

The exercise program will be based on supervised aerobic and resistance exercise home-based training sessions 3 times/week. The sessions will be 60 minutes long and will include 5 minutes of flexibility, followed by 25 minutes of aerobic exercises, 25 minutes of resistance exercises, and 5 minutes of balance exercises. The physiotherapist will supervise the sessions and will provide monthly individual face-to-face counselling to assure adherence to the protocol. The investigators have designed an individualized exercise program that fits the current patient's clinical situation. Each patient will receive a fitness tracker band to monitor his/her activity.

Behavioural support will include problem-solving strategies and practical tools to facilitate participants' self-control on emotional eating or stress-driven behaviours. Targeted behaviour goals will be set. A psychologist will provide technical support and training to the dietitian and the physiotherapist to improve their skills to provide behavioural changes and motivation.

03

Conditions studied

  • Obesity
  • Solid Neoplasm
  • Stage II-IV
  • Curative Treatment

Keywords

  • Obesity
  • Neoplasms
  • Antineoplasic agents
  • Chemotherapy
  • Radiotherapy
  • Weight Loss
  • Physical Activity
  • Feasibility Studies
  • Patient Compliance
  • Patient Motivation
  • Patient Adherence
  • Patient Dropouts
  • Treatment-related adverse effects
  • Biomarkers
  • nutritional intervention
  • curative-intent treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (age 18+) with confirmed malignant solid tumors, stage II-IV, elected for oncological treatment (chemo, radio, or both) with curative intend.
  • Expected oncological treatment time ≥ 3 months.
  • ≥ 30 kg/m²
  • Resident in the Barcelona area up to the completion of cancer treatment.
  • Perfomance Status (PS) 0-1
  • Availability of internet access.

Exclusion criteria

Exclusion Criteria:

  • Patients with melanoma and brain tumours.
  • Surgery as the only treatment.
  • Tumour localizations with high risk of malnutrition (such as head and neck, upper gastrointestinal tract, or pancreatic cancer):
  • Pregnancy or breastfeeding
  • Another active
  • Current health or medical condition that affects weight status, e.g., untreated hyper- or hypothyroidism,etc
  • Pre-existing medical condition that precludes adherence to unsupervised exercise, e.g., severe orthopedic conditions, scheduled for a hip or knee replacement, bone , paralysis, dementia, untreated stage 3 hypertension, or unstable angina, heart attack, congestive heart failure or conditions that dictated hospitalization or oxygen within 6-months.
  • Unable to read or understand Spanish or Catalan
  • Enrolled in a weight loss program
  • Active suicidal ideation, anorexia, bulimia, binge eating disorder, current substance abuse or dependence (besides nicotine dependence)
  • Use of pacemaker or another electrical implanted device
  • History of bariatric (or LapBand) surgery, or considering or currently on a wait-list for bariatric or LapBand surgery
  • Patients with any concurrent medical or psychological condition that, in the investigator's opinion, would jeopardize the safety of the patient or compliance with the protocol.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Cancer patients with obesity with active curative treatment

    Fifty adult cancer patients with obesity (BMI ≥30 kg/m²) newly diagnosed with stage II-IV solid tumors undergoing curative-intent treatment. Participants will receive a multimodal weight management program combining dietary intervention, physicial activity and behavioral support.

    Behavioral: Multimodal weight management program

Interventions

  • BehavioralMultimodal weight management program

    This intervention consists of three components: * Nutritional Counseling: * A personalized hypocaloric and high-protein diet is prescribed, based on individual energy requirements with a 20% caloric reduction. * The protein intake target is 1.5 g/kg/day to promote fat loss while maintaining muscle mass. * Exercise Program * Home-based, supervised aerobic and resistance training sessions conducted 3 times per week. * Each 60-minute session includes: 5 minutes flexibility, 25 minutes aerobic training, 25 minutes resistance training, and 5 minutes balance exercises. * Behavioral Support * Patients receive training in problem-solving strategies, motivation, and emotional self-regulation to improve adherence to both dietary and exercise goals. * Health professionals delivering the intervention are trained in behavior change techniques by a clinical psychologist.

06

What researchers measure

Primary outcomes

  1. Accrual

    Feasibility will be evaluated based on participant accrual, measured by the weekly enrollment rate and the total duration required to achieve the target sample size.

    Time frame: From baseline to end of cancer treatment (3 to 9 months)

  2. Retention

    Feasibility will be assessed based on participant retention, monitored through attendance records signed at each visit. Investigators will calculate the retention rate, dropout rate, time to dropout, and reasons for discontinuation.

    Time frame: From baseline to end of cancer treatment (3 to 9 months)

  3. Fidelity of the programme delivery

    Feasibility based on fidelity of the intervention will be assessed using a patient-completed checklist after each dietetic and physiotherapy session. Items will be scored as: +1: session content delivered as intended, 0: content omitted, -1: content delivered in a way that deviates from protocol. Fidelity scores will be aggregated, and if overall fidelity drops below 80%, retraining may be considered. Additionally, patients will complete a final evaluation form at the end of the program assessing intervention load, frequency, delivery format, behavioral support, and perceived value (e.g., effort, satisfaction, willingness to repeat).

    Time frame: From baseline to end of cancer treatment (3 to 9 months)

  4. Nutritional adherence

    Feasibility based on adherence will be evaluated using a 24-hour dietary recall to assess energy and protein intake. At the end of the intervention period, dietary adherence will also be defined as a 10-20% reduction in baseline calorie intake, along with maintenance or an increase in protein intake.

    Time frame: From baseline to end of cancer treatment (3 to 9 months)

  5. Physical activity adherence

    Feasibility based on physical activity adherence will be assessed through physiotherapist evaluations and wearable device tracking.

    Time frame: From baseline to end of cancer treatment (3 to 9 months)

  6. Ocurrance of any serious or life-threatening adverse events (Safety)

    Safety will be evaluated by monitoring the occurrence of any serious or life-threatening adverse events that may be attributable to the intervention. Specifically, investigators will record physical or cardiac events resulting in overnight hospitalization. The clinical team will assess and document whether each event is related to the dietary, exercise, or behavioral components of the intervention.

    Time frame: Throughout the study period (from baseline to end of intervention, 3 to 9 months)

Secondary outcomes

  1. Change in Body Weight and Body Composition

    Assessed by bioelectrical impedance analysis (BIA, InBody S10) at each dietetic visit. Measures include total weight change (kg), fat mass (kg), and preservation of muscle mass. In patients with available imaging, body composition will be analyzed using CT scan at the L3 vertebral level.

    Time frame: Baseline to end of treatment (approx. 3 to 9 months)

  2. Change in Eating Self-Efficacy

    Eating self-efficacy will be assessed using the scenario-based Dieting Self-Efficacy Scale (DIET-SE), consisting of 11 items evaluating confidence in managing challenges to dietary self-control. Responses to each item are assessed on a Likert-type rating scale ranging from 0 (not at all confident) to 4 (very con-fident).

    Time frame: Baseline to the end of intervention (approx. 3 to 9 months)

  3. Change in physical activity self-efficacy

    Exercise self-efficacy will be assessed using the modified Physical Activity Self-Efficacy Scale. A five-point Likert scale ranging from not at all confident (1) to very confident (5) will be used, higher scores indicating greater self-efficacy. Assessments will be conducted at baseline and at the end of the intervention.

    Time frame: Baseline to the end of intervention (approx. 3 to 9 months)

  4. Change in Autonomous Motivation

    Autonomous motivation will be assessed using an adapted and abbreviated version of the Treatment Self-Regulation Questionnaire (TSRQ). This scale includes four items rated on a 5-point Likert scale ranging from 1 ("not at all true") to 5 ("very true"). Higher scores indicate greater autonomous motivation toward behavior change. One-to-one psychological support may be offered to participants with low scores to enhance engagement.

    Time frame: Baseline to the end of intervention (approx. 3 to 9 months)

  5. Modified Glasgow Prognostic Score

    Serum albumin and C-reactive protein levels will be used to calculate the Modified Glasgow Prognostic Score (mGPS) as a measure of systemic inflammation. Blood samples will be collected at baseline and at the end of the intervention, coinciding with routine clinical assessments.

    Time frame: Baseline and end of treatment (3 to 9 months)

07

Study locations

1 of 1 sites recruiting
  • Institut Català d'Oncologia. Catalan Institute of Oncology
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
    Recruiting
08

References and documents

Publications

  • Llenas-Blade A, Puig Figueras M, Padilla Padilla C, Esteve A, Zamora-Ros R, Daura I Vidal M, Ochoa-Arnedo C, Pernas S, Santos Vivas C, Brenes J, Jimenez-Colomo L, Asiain L, Nadal E, Arribas L. Weight management in obese cancer patients during curative active treatment: protocol for the CANOBESE feasibility study. Pilot Feasibility Stud. 2026 Jun 24. doi: 10.1186/s40814-026-01868-w. Online ahead of print. PubMed 42343485 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Mar 2027, 20 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 20 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Mar 2027, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2025
First posted
Jul 10, 2025
StartActual
Jul 22, 2025
Primary completionEst.
Mar 2027was Aug 2026
CompletionEst.
Mar 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Mar 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Aug 2026→Mar 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07058207
Lead sponsor
Institut d'Investigació Biomèdica de Bellvitge
Collaborators
World Cancer Research Fund International, Institut Català d'Oncologia
Responsible party
Lorena Arribas (Principal Investigator, Institut d'Investigació Biomèdica de Bellvitge) — Principal investigator
First posted
Jul 10, 2025
Start date
Jul 22, 2025
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Lorena Arribas
Contact
larribas@iconcologia.net
+34932607751
Marta Puig
Contact
mpuig@iconcologia.net
+34932607751
Lorena Arribas, PhD, MsC, RD
principal investigator · Catalan Institute of Oncology (ICO-Hospitalet). Bellvitge Biomedical Research Institute (IDIBELL)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion